IL176830A0 - Nk-1 receptor antagonists to improve anesthesia recovery - Google Patents
Nk-1 receptor antagonists to improve anesthesia recoveryInfo
- Publication number
- IL176830A0 IL176830A0 IL176830A IL17683006A IL176830A0 IL 176830 A0 IL176830 A0 IL 176830A0 IL 176830 A IL176830 A IL 176830A IL 17683006 A IL17683006 A IL 17683006A IL 176830 A0 IL176830 A0 IL 176830A0
- Authority
- IL
- Israel
- Prior art keywords
- receptor antagonists
- anesthesia recovery
- improve anesthesia
- improve
- recovery
- Prior art date
Links
- 206010002091 Anaesthesia Diseases 0.000 title 1
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 title 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 title 1
- 230000037005 anaesthesia Effects 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 238000011084 recovery Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Surgery (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54069704P | 2004-01-30 | 2004-01-30 | |
| PCT/IB2005/000010 WO2005082366A1 (en) | 2004-01-30 | 2005-01-06 | Nk-1 receptor antagonists anesthesia recovery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL176830A0 true IL176830A0 (en) | 2006-10-31 |
Family
ID=34910695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL176830A IL176830A0 (en) | 2004-01-30 | 2006-07-13 | Nk-1 receptor antagonists to improve anesthesia recovery |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20070155782A1 (https=) |
| EP (1) | EP1713479A1 (https=) |
| JP (1) | JP2007519701A (https=) |
| KR (1) | KR100880391B1 (https=) |
| CN (1) | CN1913893A (https=) |
| AU (1) | AU2005216706B2 (https=) |
| BR (1) | BRPI0507325A (https=) |
| CA (1) | CA2554823A1 (https=) |
| IL (1) | IL176830A0 (https=) |
| MX (1) | MXPA06007964A (https=) |
| NO (1) | NO20062965L (https=) |
| RU (1) | RU2337685C2 (https=) |
| WO (1) | WO2005082366A1 (https=) |
| ZA (1) | ZA200605149B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5021318B2 (ja) | 2004-01-30 | 2012-09-05 | ファイザー・プロダクツ・インク | β−シクロデキストリンを液体投薬形態に用いて多用量製剤を達成するための抗菌性防腐剤 |
| US9446029B2 (en) | 2010-07-27 | 2016-09-20 | Colorado State University Research Foundation | Use of NK-1 receptor antagonists in management of visceral pain |
| RU2489765C1 (ru) * | 2012-01-10 | 2013-08-10 | Открытое акционерное общество "Научно-исследовательский институт газоразрядных приборов "Плазма" (ОАО "Плазма") | Способ изготовления газонаполненного разрядника |
| CN114984223B (zh) * | 2022-05-31 | 2023-06-20 | 中国人民解放军陆军军医大学第二附属医院 | 生长激素促分泌素受体拮抗剂在制备吸入麻醉复苏制剂中的应用 |
| AT527172A1 (de) * | 2023-04-25 | 2024-11-15 | Vetviva Richter Gmbh | Maropitantformulierung |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US540644A (en) | 1895-06-11 | del yalle | ||
| US540897A (en) | 1895-06-11 | Harold f | ||
| UA27776C2 (uk) * | 1991-05-31 | 2000-10-16 | Пфайзер Інк. | Похідні хінуклідину та їх фармацевтично прийнятні солі, що є антагоністами речовини р у ссавців, фармацевтична композиція, що має антагоністичну дію на речовину р у ссавців |
| US5393762A (en) * | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
| US6255320B1 (en) | 1999-06-01 | 2001-07-03 | Pfizer Inc. | Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions |
| SK252004A3 (sk) | 2001-07-20 | 2005-03-04 | Pfizer Products Inc. | Použitie antagonistov receptora NK-1 na výrobu liečiva na liečenie abnormálneho úzkostného správania domácich zvierat a spôsob screeningu skúšanej zlúčeniny s cieľom stanoviť anxiolytickú účinnosť u psov |
-
2005
- 2005-01-06 MX MXPA06007964A patent/MXPA06007964A/es not_active Application Discontinuation
- 2005-01-06 CN CNA2005800036680A patent/CN1913893A/zh active Pending
- 2005-01-06 AU AU2005216706A patent/AU2005216706B2/en not_active Ceased
- 2005-01-06 RU RU2006126828/15A patent/RU2337685C2/ru not_active IP Right Cessation
- 2005-01-06 BR BRPI0507325-1A patent/BRPI0507325A/pt not_active IP Right Cessation
- 2005-01-06 US US10/587,590 patent/US20070155782A1/en not_active Abandoned
- 2005-01-06 WO PCT/IB2005/000010 patent/WO2005082366A1/en not_active Ceased
- 2005-01-06 EP EP05702181A patent/EP1713479A1/en not_active Withdrawn
- 2005-01-06 JP JP2006550323A patent/JP2007519701A/ja not_active Withdrawn
- 2005-01-06 KR KR1020067015267A patent/KR100880391B1/ko not_active Expired - Fee Related
- 2005-01-06 CA CA002554823A patent/CA2554823A1/en not_active Abandoned
-
2006
- 2006-06-22 ZA ZA200605149A patent/ZA200605149B/en unknown
- 2006-06-26 NO NO20062965A patent/NO20062965L/no not_active Application Discontinuation
- 2006-07-13 IL IL176830A patent/IL176830A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2337685C2 (ru) | 2008-11-10 |
| MXPA06007964A (es) | 2007-01-26 |
| KR20060127934A (ko) | 2006-12-13 |
| AU2005216706B2 (en) | 2007-11-29 |
| ZA200605149B (en) | 2007-11-28 |
| CA2554823A1 (en) | 2005-09-09 |
| JP2007519701A (ja) | 2007-07-19 |
| AU2005216706A1 (en) | 2005-09-09 |
| CN1913893A (zh) | 2007-02-14 |
| WO2005082366A1 (en) | 2005-09-09 |
| NO20062965L (no) | 2006-07-21 |
| RU2006126828A (ru) | 2008-03-10 |
| KR100880391B1 (ko) | 2009-01-30 |
| EP1713479A1 (en) | 2006-10-25 |
| WO2005082366A8 (en) | 2005-12-15 |
| US20070155782A1 (en) | 2007-07-05 |
| BRPI0507325A (pt) | 2007-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI372751B (en) | Pyrimidines as prostaglandin d2 receptor antagonists | |
| IL189866A0 (en) | Histamine-3 receptor antagonists | |
| ZA200606314B (en) | Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists | |
| ZA200702790B (en) | Thrombin receptor antagonists | |
| IL183538A0 (en) | Substituted piperazines as cb1 antagonists | |
| IL192309A0 (en) | Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists | |
| ZA200705449B (en) | 2-phenyl-indoles as prostaglandin D2 receptor antagonists | |
| IL188806A0 (en) | Substituted piperazines as metabotropic glutamate receptor antagonists | |
| IL190686A0 (en) | Il-21 receptor antagonists | |
| IL237513A0 (en) | Piperazindiones as oxytocin receptor antagonists | |
| ZA200800320B (en) | Indol-3-carbonyl-spiro-piperidine derivatives as Via receptor antagonists | |
| PL1951661T3 (pl) | Antagoniści receptora glukagonu, wytwarzanie i terapeutyczne zastosowania | |
| SI1951658T1 (sl) | Antagonisti glukagonskega receptorja priprava interapevtska uporaba | |
| TWI341198B (en) | Hydroisoindoline tachykinin receptor antagonists | |
| EP1812008A4 (en) | ANTAGONISTS OF THE IL-8 RECEPTOR | |
| ZA200801033B (en) | Acetylenic piperazines as metabotropic glutamate receptor antagonists | |
| IL178622A0 (en) | Piperazinylpiperidine derivatives as chemokine receptor antagonists | |
| ZA200801034B (en) | Bicyclic piperazines as metabotropic glutamate receptor antagonists | |
| IL176830A0 (en) | Nk-1 receptor antagonists to improve anesthesia recovery | |
| IL185640A0 (en) | Use of 2-anilino-3 ,4-dihydro-quinazolines as 5ht5a receptor antagonists | |
| IL179518A0 (en) | Mercaptoimidazoles as ccr2 receptor antagonists | |
| ZA200605574B (en) | Hydroisoindoline tachykinin receptor antagonists | |
| GB0525029D0 (en) | Receptor Antagonist | |
| SI1711465T1 (sl) | Antagonisti hidroizoindolin tahikininskega receptorja | |
| ZA200608369B (en) | Piperazinylpiperidine derivatives as chemokine receptor antagonists |